The first-line mCRPC market is highly competitive due to the availability of several efficacious and safe hormonal agents that are well entrenched in this indication. Although these therapies have improved patient outcomes, significant unmet need still remains for novel therapies to build upon these outcomes and provide further benefits to first-line mCRPC patients. In this report, we examine the most important drivers of prescribing behavior and key unmet needs in this indication, and provide an in-depth analysis of the most significant commercial opportunities.

Table of contents

  • Detailed, Expanded Analysis: First-Line Metastatic Castrate-Resistant Prostate Cancer
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Non-Clinical Attributes
        • Rationale for Treatment Drivers and Goals Selection
      • Physician Rating of Treatment Drivers and Goals in First-Line Metastatic Castrate-Resistant Prostate Cancer
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Stated Versus Derived Importance of Key Treatment Drivers and Goals
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in First-Line Metastatic Castrate-Resistant Prostate Cancer
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Unmet Need in First-Line Metastatic Castrate-Resistant Prostate Cancer and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the First-Line Metastatic Castrate-Resistant Prostate Cancer Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent That Prolongs Overall Survival
        • Opportunity: A Novel Agent That Delays Disease Progression
        • Opportunity: A Novel Agent That Offers Improved Pain Palliation for Patients with Symptomatic Bone Metastases
        • Opportunity: A Novel Agent That Improves PSA Response Rate
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2

Author(s): Evrim Gurpinar

Evrim Gurpinar, is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Evrim was a Postdoctoral Fellow at the Cancer Research UK Beatson Institute, where he studied the effects of p53 tumor suppressor mutations on cancer cell metabolism. He received his in Cell and Molecular Biology from Tulane University as a Fulbright Scholar and his from the University of Alabama at Birmingham School of Medicine. His PhD work entailed a preclinical drug development project to identify novel drug candidates for non-small cell lung cancer.


Related Reports

Prostate Cancer | Landscape & Forecast | Disease Landscape & Forecast

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga...

View Details

Prostate Cancer | Current Treatment | Detailed, Expanded Analysis (US)

Hormonal therapies have dominated the treatment of prostate cancer for the past decade. Zytiga (Janssen, generics) and Xtandi (Medivation / Astellas Pharma), initially approved for metastatic cas...

View Details

Prostate Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key prostate cancer patie...

View Details

Prostate Cancer | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into...

View Details